GENE ONLINE|News &
Opinion
Blog

FDA Authorizes Pfizer/BioNTech’s COVID-19 Vaccine for 12 to 15 Year Olds

by Rajaneesh K. Gopinath
Share To

On May 10th, the U.S. Food and Drug Administration (FDA) expanded the emergency use authorization (EUA) of Pfizer/BioNTech’s BNT162b2 to prevent COVID-19 in teens and adolescents. The agency amended the original EUA granted on December 11th, 2020, to include individuals ages 12 to 15.

BNT162b2 was the first COVID-19 vaccine to receive emergency approval in the US for people 16 years and up. With this expansion, the mRNA vaccine also becomes the first to be FDA approved for the 12-15 age group.

“The FDA’s expansion of the emergency use authorization for the Pfizer-BioNTech COVID-19 Vaccine to include adolescents 12 through 15 years of age is a significant step in the fight against the COVID-19 pandemic,” said Acting FDA Commissioner Janet Woodcock, M.D.

 

Return to Normalcy

The CDC notes that at least 1.5 million COVID-19 cases have been reported in individuals 11 to 17 years of age since March 2020. Although the infection is milder in children than adults, those with underlying medical conditions are still at risk for contracting severe COVID-19. Besides, they can also spread the virus to others just as adults. This vaccine approval would help young teens who have spent over a year in isolation and virtual learning to return to normalcy gradually.

“Today’s action allows for a younger population to be protected from COVID-19, bringing us closer to returning to a sense of normalcy and to ending the pandemic. Parents and guardians can rest assured that the agency undertook a rigorous and thorough review of all available data, as we have with all of our COVID-19 vaccine emergency use authorizations.” Woodcock added.

In late March, Pfizer reported that the vaccine showed 100% efficacy in a trial conducted in the US with 2,260 participants. The FDA decided to expand the EUA after reviewing the available safety and efficacy data.

The Vaccines and Related Biological Products Advisory Committee (VRBPAC), an independent panel of the FDA, did not convene to recommend the expansion. However, the US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices will meet on Wednesday to advise the CDC to recommend vaccination for 12-to-15-year-olds. If greenlit by the panel, the vaccine will be available for the new age group as soon as Thursday in some states.

“Having a vaccine authorized for a younger population is a critical step in continuing to lessen the immense public health burden caused by the COVID-19 pandemic,” said Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research.

“With science guiding our evaluation and decision-making process, the FDA can assure the public and medical community that the available data meet our rigorous standards to support the emergency use of this vaccine in the adolescent population 12 years of age and older,” he added.

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
R&D
Breakthrough Screening Platform to Assess SARS-CoV-2 Mutations and Potential Treatments
2024-04-16
FDA Requests for a $7.2 Billion Budget in FY 2025 for Critical Health Initiatives
2024-03-12
LATEST
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
Taiwan Breakthrough: Next-Generation Sequencing Now Covered in Health Insurance, Benefitting 20,000 Cancer Patients Annually
2024-05-02
CellTech Accelerator and Cyto-Facto Inc. Forge Strategic Partnership to Advance CGT Industry Growth
2024-04-29
Kaiser’s Data Breach: 13.4 Million Affected in Healthcare Conglomerates Privacy Crisis
2024-04-26
Mechanisms of Allograft Rejection: Insights from Behind the Scenes
2024-04-25
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
EVENT
Scroll to Top